161 related articles for article (PubMed ID: 22947062)
1. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban.
Harenberg J; Marx S; Weiss C; Krämer R; Samama M; Schulman S;
J Thromb Haemost; 2012 Jul; 10(7):1433-6. PubMed ID: 22947062
[No Abstract] [Full Text] [Related]
2. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.
Tripodi A; Chantarangkul V; Guinet C; Samama MM
J Thromb Haemost; 2011 Jan; 9(1):226-8. PubMed ID: 20942848
[No Abstract] [Full Text] [Related]
3. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
4. Assays for measuring rivaroxaban: their suitability and limitations.
Lindhoff-Last E; Samama MM; Ortel TL; Weitz JI; Spiro TE
Ther Drug Monit; 2010 Dec; 32(6):673-9. PubMed ID: 20844464
[TBL] [Abstract][Full Text] [Related]
5. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
Samama MM; Contant G; Spiro TE; Perzborn E; Guinet C; Gourmelin Y; Le Flem L; Rohde G; Martinoli JL;
Thromb Haemost; 2012 Feb; 107(2):379-87. PubMed ID: 22187012
[TBL] [Abstract][Full Text] [Related]
7. Facts and artefacts of coagulation assays for factor Xa inhibitors.
Haas S
Thromb Haemost; 2010 Apr; 103(4):686-8. PubMed ID: 20174751
[No Abstract] [Full Text] [Related]
8. Comparative sensitivity of commonly used thromboplastins to ex vivo therapeutic rivaroxaban levels.
Arachchillage DR; Efthymiou M; Lawrie AS; Machin SJ; Mackie IJ; Cohen H
Thromb Haemost; 2014 Aug; 112(2):421-3. PubMed ID: 24671135
[No Abstract] [Full Text] [Related]
9. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
[TBL] [Abstract][Full Text] [Related]
10. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.
Molenaar PJ; Dinkelaar J; Leyte A
Clin Chem Lab Med; 2012 Oct; 50(10):1799-807. PubMed ID: 23089710
[TBL] [Abstract][Full Text] [Related]
11. The in-vitro anticoagulant effect of rivaroxaban in neonates.
Attard C; Monagle P; Kubitza D; Ignjatovic V
Blood Coagul Fibrinolysis; 2014 Apr; 25(3):237-40. PubMed ID: 24418940
[TBL] [Abstract][Full Text] [Related]
12. Correlating prothrombin time with plasma rivaroxaban level.
Rodgers R; Bagot CN; Lawrence C; Hickman G; McGurk M; Tait RC
Br J Haematol; 2013 Dec; 163(5):685-7. PubMed ID: 24219334
[No Abstract] [Full Text] [Related]
13. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban.
Gerotziafas GT; Baccouche H; Sassi M; Galea V; Chaari M; Hatmi M; Samama MM; Elalamy I
Thromb Res; 2012 Jan; 129(1):101-3. PubMed ID: 22000405
[No Abstract] [Full Text] [Related]
14. Test of the month: The chromogenic antifactor Xa assay.
Gehrie E; Laposata M
Am J Hematol; 2012 Feb; 87(2):194-6. PubMed ID: 22081480
[TBL] [Abstract][Full Text] [Related]
15. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
[TBL] [Abstract][Full Text] [Related]
16. Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™.
Casutt M; Konrad C; Schuepfer G
Anaesthesist; 2012 Nov; 61(11):948-53. PubMed ID: 23053307
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial.
Samama MM; Contant G; Spiro TE; Perzborn E; Flem LL; Guinet C; Gourmelin Y; Martinoli JL;
Clin Appl Thromb Hemost; 2012; 18(2):150-8. PubMed ID: 22387577
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.
Dale BJ; Ginsberg JS; Johnston M; Hirsh J; Weitz JI; Eikelboom JW
J Thromb Haemost; 2014 Nov; 12(11):1810-5. PubMed ID: 25196577
[TBL] [Abstract][Full Text] [Related]
19. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
Samama MM
Thromb Res; 2011 Jun; 127(6):497-504. PubMed ID: 20888031
[TBL] [Abstract][Full Text] [Related]
20. Laboratory monitoring of the non-vitamin K oral anticoagulants.
Blann AD; Lip GY
J Am Coll Cardiol; 2014 Sep; 64(11):1140-2. PubMed ID: 25212649
[No Abstract] [Full Text] [Related]
[Next] [New Search]
